Entecavir HydrateAntiviral drug used in hepatitis B infection CAS# 209216-23-9 |
- Emtricitabine
Catalog No.:BCC3774
CAS No.:143491-57-0
- Tenofovir
Catalog No.:BCC2500
CAS No.:147127-20-6
- Tenofovir Disoproxil Fumarate
Catalog No.:BCC1108
CAS No.:202138-50-9
- Lersivirine
Catalog No.:BCC1698
CAS No.:473921-12-9
- Didanosine
Catalog No.:BCC3763
CAS No.:69655-05-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 209216-23-9 | SDF | Download SDF |
| PubChem ID | 170342 | Appearance | Powder |
| Formula | C12H15N5O3.H2O | M.Wt | 295.29 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | SQ 34676; BMS-200475 | ||
| Solubility | DMSO : ≥ 50 mg/mL (169.33 mM) H2O : 2.8 mg/mL (9.48 mM; Need ultrasonic and warming) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-amino-9-[(3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one;hydrate | ||
| SMILES | C=C1C(CC(C1CO)O)N2C=NC3=C2NC(=NC3=O)N.O | ||
| Standard InChIKey | YXPVEXCTPGULBZ-JBDQBEHPSA-N | ||
| Standard InChI | InChI=1S/C12H15N5O3.H2O/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20;/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20);1H2/t6-,7?,8-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Entecavir monohydrate (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.In Vitro:BMS-200475 has a EC50 of 3.75 nM against HBV. It is incorporated into the protein primer of HBV and subsequently inhibits the priming step of the reverse transcriptase. The antiviral activity of BMS-200475 is significantly less against the other RNA and DNA viruses[1]. Entecavir is more readily phosphorylated to its active metabolites than other deoxyguanosine analogs (penciclovir, ganciclovir, lobucavir, and aciclovir) or lamivudine. The intracellular half-life of entecavir is 15 h[2].In Vivo:Daily oral treatment with BMS-200475 at doses ranging from 0.02 to 0.5 mg/kg of body weight for 1 to 3 months effectively reduces the level of woodchuck hepatitis virus (WHV) viremia in chronically infected woodchucks[3]. References: | |||||
Entecavir Hydrate Dilution Calculator
Entecavir Hydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.3865 mL | 16.9325 mL | 33.865 mL | 67.73 mL | 84.6625 mL |
| 5 mM | 0.6773 mL | 3.3865 mL | 6.773 mL | 13.546 mL | 16.9325 mL |
| 10 mM | 0.3387 mL | 1.6933 mL | 3.3865 mL | 6.773 mL | 8.4663 mL |
| 50 mM | 0.0677 mL | 0.3387 mL | 0.6773 mL | 1.3546 mL | 1.6933 mL |
| 100 mM | 0.0339 mL | 0.1693 mL | 0.3387 mL | 0.6773 mL | 0.8466 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Entecavir hydrate is a reverse transcriptase inhibitor.
Reverse transcriptase (RT) is used to generate complementary DNA (cDNA) from an RNA template, which is mainly associated with retroviruses, such as HBV.
Entecavir hydrate is an oral antiviral drug used in the treatment of hepatitis B virus (HBV) infection. In 17 patients with hepatitis B virus (HBV) genotype C, treatment with peginterferon
(PEG-IFN) a-2b combination with entecavir hydrate (ETV) for 48 weeks. Among 11 patients exhibited pretherapy HBeAg, 8 showed HBeAg seroconversion. Serum HBV DNA levels reduced by 5.2 and 3.3 log copies/ml by the end of the therapy and follow-up periods, respectively. Intrahepatic cccDNA reduced to 1.4 log copies/mg.
References:
[1]. Hagiwara S, Kudo M, Osaki Y, et al. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. J Med Virol, 2013, 85(6): 987-995.
- Obtucarbamate B
Catalog No.:BCN3937
CAS No.:20913-18-2
- Mangochinine
Catalog No.:BCN4913
CAS No.:209115-67-3
- JWH 073
Catalog No.:BCC1674
CAS No.:208987-48-8
- Swertianin
Catalog No.:BCC8258
CAS No.:20882-75-1
- Testosterone benzoate
Catalog No.:BCC9166
CAS No.:2088-71-3
- Saikosaponin D
Catalog No.:BCN1088
CAS No.:20874-52-6
- (1R,1'S,3'R/1R,1'R,3'S)-L-054,264
Catalog No.:BCC7364
CAS No.:208706-12-1
- Ermanin
Catalog No.:BCN4912
CAS No.:20869-95-8
- Boc-His(Boc)-OH
Catalog No.:BCC3399
CAS No.:20866-46-0
- Berberine
Catalog No.:BCN4911
CAS No.:2086-83-1
- Primulic Acid 2
Catalog No.:BCC8237
CAS No.:208599-88-6
- H-Tle-OH
Catalog No.:BCC2659
CAS No.:20859-02-3
- Fmoc- ß-HoAsp(OtBu)-OH
Catalog No.:BCC3230
CAS No.:209252-17-5
- Neocryptomerin
Catalog No.:BCN8023
CAS No.:20931-36-6
- Beta-mangostin
Catalog No.:BCN1213
CAS No.:20931-37-7
- Platycoside A
Catalog No.:BCN3241
CAS No.:209404-00-2
- VX-745
Catalog No.:BCC3966
CAS No.:209410-46-8
- 1-(2-Amino-5-chlorophenyl)-1-(trifluoromethyl)-3-cyclopropyl-2-propyn-1-ol
Catalog No.:BCC8404
CAS No.:209414-27-7
- SB271046
Catalog No.:BCC5057
CAS No.:209481-20-9
- SB 271046 hydrochloride
Catalog No.:BCC1924
CAS No.:209481-24-3
- Isotanshinone IIA
Catalog No.:BCN2501
CAS No.:20958-15-0
- Isotanshinone I
Catalog No.:BCN2500
CAS No.:20958-17-2
- Dihydroisotanshinone I
Catalog No.:BCN2308
CAS No.:20958-18-3
- CART (55-102) (rat)
Catalog No.:BCC6006
CAS No.:209615-79-2
Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.[Pubmed:23588724]
J Med Virol. 2013 Jun;85(6):987-95.
The ideal approach to treat chronic hepatitis B remains controversial. This pilot study aimed to evaluate the effectiveness of peginterferon (PEG-IFN) alpha-2b and Entecavir Hydrate (ETV) as a combination therapy for patients with chronic hepatitis B, particularly in the context of virological response and the reduction of intrahepatic covalently closed circular DNA (cccDNA). A total of 17 patients with hepatitis B virus (HBV) genotype C were enrolled in this study. All subjects were treated with this combination therapy for 48 weeks and observed for an additional 24 weeks. All patients underwent liver biopsy before and after the therapy period. Changes in cccDNA levels and liver histology were monitored between biopsies. Among the 11 patients who exhibited pre-therapy hepatitis B e antigen (HBeAg), 8 (73%) showed evidence of HBeAg seroconversion by the end of the follow-up period. Serum HBV DNA levels decreased by 5.2 and 3.3 log copies/ml (mean) by the end of the therapy and follow-up periods, respectively. In addition, intrahepatic cccDNA decreased significantly to 1.4 log copies/microg (mean) by the end of the therapy period. Among the 11 patients who did not experience viral relapse, only 2 (18%) exhibited high levels of cccDNA (>4.5 log copies/microg) by the end of the treatment period. In contrast, all relapsed subjects exhibited significantly higher levels of cccDNA than subjects who did not relapse (P = 0.027). The combination regimen is a promising approach to treat chronic hepatitis B and may achieve significant reduction in serum HBV DNA and intrahepatic cccDNA. Wiley Periodicals, Inc.
